Arq, Inc. headed into its Q1 2026 earnings — reported after the close on May 6 — carrying the weight of a brutal March selloff, and delivered a beat on both lines.
Q1 EPS came in at -$0.02, ahead of the -$0.04 estimate. Revenue hit $29.1M, topping the $27.8M consensus. But alongside the results, the company announced a strategic optimization review for its granular activated carbon (GAC) production, with a target to complete the review and set GAC strategy by Q3 2026. That headline adds a layer of uncertainty that a modest earnings beat may not fully resolve.
The backdrop is one of the sharpest reactions on record for this stock. In March, after the prior earnings release, ARQ fell nearly 49% in a single session, extending to a five-day loss of around 41%. That episode frames everything about how the market is currently positioned — insiders responded almost immediately, and short sellers have been gradually stepping back.
Short positioning has been quietly unwinding. SI now runs at roughly 3.7% of the free float — down nearly 10% over the past month and off around 2.6% on the week. Borrow conditions are relaxed: cost to borrow is just 0.56%, and availability is extremely loose at over 2,800% of short interest, meaning shares are plentiful in the lending pool relative to current shorts. The ORTEX short score of 37, down from around 40 two weeks ago, confirms the bearish thesis has been losing momentum. Options traders agree — the put/call ratio at 0.022 is below its 20-day average of 0.029, sitting near the lower end of its 52-week range. There is no sign of defensive positioning in the options market heading into the print.
The analyst picture has been one of stubborn optimism meeting a falling knife. Both active covering firms maintained Buy ratings in March after the crash, but trimmed targets sharply: Canaccord Genuity cut from $7.50 to $5.00, and Clear Street moved from $8.00 to $6.50. The consensus mean target is $3.63 against a closing price of $2.37, implying meaningful upside on paper — but these targets were set on March 11, and the stock has traded sideways since. The EV/EBITDA multiple is running at 7.1x, down roughly half a point over the past month. Price-to-book is just 0.62x. The EPS surprise factor score ranks in the 99th percentile — the company has a habit of beating estimates, which the Q1 print confirms.
The insider response to the March collapse is worth noting. Director Richard Campbell-Breeden bought 150,000 shares at around $2.21 on March 23, spending $332K. On the same day, the CTO picked up shares at similar levels. An independent director added 77,500 shares in mid-March at roughly $1.95. Against those purchases, some smaller tax-related sells went through on the same date from the CEO, General Counsel, and CFO — all at nominal values. Net insider activity over the 90-day window amounts to about 313,000 shares bought at a cost of roughly $729K. The cluster of buying at post-crash lows signals that those closest to the business saw the selloff as an overreaction.
The Q1 beat and the strategic review announcement are the focus now. Whether the GAC review resolves into a credible growth reset — or confirms the business model pressures that triggered March's selloff — is the question the May 7 earnings call will need to answer.
See the live data behind this article on ORTEX.
Open ARQ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
